Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322044 | 0.85 | EPHX2 (0.54) | HPGDNPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3323983 | 0.85 | HPGD (0.56) | HPGDKMT2AMEN1LMNAHTT | |
| SCHEMBL13333553 | 0.85 | CNR2 (0.50) | NPC1ALDH1A1LMNAEPHX2MAPK1 | |
| SCHEMBL13333544 | 0.82 | CNR2 (0.49) | HPGDKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL3323745 | 0.82 | MEN1 (0.50) | HPGDKMT2AMEN1ALDH1A1EPHX2 | |
| SCHEMBL3327170 | 0.79 | EPHX2 (0.53) | NPC1KMT2AMEN1ALDH1A1EPHX2 | |
| SCHEMBL13333545 | 0.78 | MEN1 (0.56) | HPGDKMT2AMEN1ALDH1A1HTT | |
| SCHEMBL3322188 | 0.78 | ALDH1A1 (0.49) | NPC1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL13333547 | 0.75 | HSD11B1 (0.54) | KMT2AMEN1ALDH1A1LMNAEPHX2 | |
| SCHEMBL8389369 | 0.75 | NPC1 (0.71) | HPGDNPC1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HPGD 330/4885NPC1 1106/4885KMT2A 3083/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | HPGD 3581/4885NPC1 2474/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.